CMS 8A8

SGD 1.71 +0.00% +0.00 Updated 17 Nov 2026, 15:46 SGT

Financials

CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025

Open annual report

Explore the statements

12 tables

Consolidated Statement of Profit or Loss and Other Comprehensive Income

27 metrics

Units appear below each metric. Scroll to compare years

Consolidated Statement of Profit or Loss and Other Comprehensive Income from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group2024Group Source
Profit or loss
RevenueRMB'000 8,212,0587,468,990 PDF p. 82
Cost of goods soldRMB'000 (2,340,522)(2,046,796) PDF p. 82
Gross profitRMB'000 5,871,5365,422,194 PDF p. 82
Other incomeRMB'000 145,672208,387 PDF p. 82
Other gains and lossesRMB'000 156,907(151,244) PDF p. 82
Selling expensesRMB'000 (2,842,252)(2,661,648) PDF p. 82
Administrative expensesRMB'000 (865,777)(780,093) PDF p. 82
Finance costsRMB'000 (20,297)(38,610) PDF p. 82
Research and development expensesRMB'000 (585,023)(329,982) PDF p. 82
Share of results of associatesRMB'000 238,790338,548 PDF p. 82
Share of result of a joint ventureRMB'000 3,5052,755 PDF p. 82
Profit before taxRMB'000 2,103,0612,010,307 PDF p. 82
Income tax expenseRMB'000 (659,784)(397,227) PDF p. 82
Profit for the yearRMB'000 1,443,2771,613,080 PDF p. 82
Other comprehensive income
Fair value gain (loss) on investments in equity instruments at fair value through other comprehensive incomeRMB'000 227,810(34,110) PDF p. 82
Share of other comprehensive (expense) income of associatesRMB'000 (6,568)6,162 PDF p. 82
Exchange differences arising on translation of foreign operationsRMB'000 (8,284)3,038 PDF p. 82
Exchange differences arising on translation of interests in associatesRMB'000 15,664(9,061) PDF p. 82
Other comprehensive income (expense) for the year, net of income taxRMB'000 228,622(33,971) PDF p. 82
Total comprehensive income
Total comprehensive income for the yearRMB'000 1,671,8991,579,109 PDF p. 82
Profit (loss) for the year attributable to
Owners of the CompanyRMB'000 1,488,8921,619,788 PDF p. 82
Non-controlling interestsRMB'000 (45,615)(6,708) PDF p. 82
SubtotalRMB'000 1,443,2771,613,080 PDF p. 82
Total comprehensive income (expense) for the year attributable to
Owners of the CompanyRMB'000 1,717,5141,585,817 PDF p. 82
Non-controlling interestsRMB'000 (45,615)(6,708) PDF p. 82
SubtotalRMB'000 1,671,8991,579,109 PDF p. 82
Earnings per share
BasicRMB per share 0.61540.6673 PDF p. 82
Definitions & sources

Only basic EPS printed. Notes column references omitted from values.

Consolidated Statement of Financial Position

36 metrics

Units appear below each metric. Scroll to compare years

Consolidated Statement of Financial Position from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group2024Group Source
Non-current assets
Property, plant and equipmentRMB'000 366,702375,893 PDF p. 83
Right-of-use assetsRMB'000 79,38872,197 PDF p. 83
Interests in associatesRMB'000 3,509,5943,389,827 PDF p. 83
Interest in a joint ventureRMB'000 172,308181,804 PDF p. 83
Intangible assetsRMB'000 2,213,7652,301,346 PDF p. 83
GoodwillRMB'000 1,511,2611,547,903 PDF p. 83
Equity instruments at fair value through other comprehensive incomeRMB'000 357,593129,783 PDF p. 83
Deposits paid for acquisition of intangible assetsRMB'000 1,480,6641,189,256 PDF p. 83
Amounts due from associatesRMB'000 30,00030,000 PDF p. 83
Deferred tax assetsRMB'000 58,79552,693 PDF p. 83
Loan receivableRMB'000 120,21672,227 PDF p. 83
SubtotalRMB'000 9,900,2869,342,929 PDF p. 83
Current assets
InventoriesRMB'000 803,958768,139 PDF p. 83
Financial assets at fair value through profit or lossRMB'000 3,084,9022,160,097 PDF p. 83
Trade and other receivables and prepaymentsRMB'000 2,258,5661,780,483 PDF p. 83
Tax recoverableRMB'000 1,2705,553 PDF p. 83
Amounts due from associatesRMB'000 448,493284,088 PDF p. 83
Bank balances and cashRMB'000 2,701,3803,706,501 PDF p. 83
SubtotalRMB'000 9,298,5698,704,861 PDF p. 83
Current liabilities
Trade and other payablesRMB'000 495,716484,797 PDF p. 83
Lease liabilitiesRMB'000 16,59716,933 PDF p. 83
Contract liabilitiesRMB'000 12,13316,610 PDF p. 83
Bank borrowingsRMB'000 651,815831,300 PDF p. 83
Tax liabilitiesRMB'000 292,962166,423 PDF p. 83
SubtotalRMB'000 1,469,2231,516,063 PDF p. 83
Net current assets
Net current assetsRMB'000 7,829,3467,188,798 PDF p. 83
Total assets less current liabilitiesRMB'000 17,729,63216,531,727 PDF p. 83
Capital and reserves
Share capitalRMB'000 83,56483,564 PDF p. 84
ReservesRMB'000 17,312,17416,227,905 PDF p. 84
Equity attributable to owners of the CompanyRMB'000 17,395,73816,311,469 PDF p. 84
Non-controlling interestsRMB'000 147,02591,639 PDF p. 84
SubtotalRMB'000 17,542,76316,403,108 PDF p. 84
Non-current liabilities
Deferred tax liabilitiesRMB'000 165,202116,109 PDF p. 84
Lease liabilitiesRMB'000 21,66712,510 PDF p. 84
SubtotalRMB'000 186,869128,619 PDF p. 84
Total (net assets funded)
SubtotalRMB'000 17,729,63216,531,727 PDF p. 84
Definitions & sources

Statement spans physical pages 83-84; table header repeated on page 84.

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Group)

14 metrics

Units appear below each metric. Scroll to compare years

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Group) from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, year ended 31 Dec 2025, RMB'0002024Group, year ended 31 Dec 2024, RMB'000 Source
Profit or loss
Profit before taxRMB'000 2,103,0612,010,307 PDF p. 82
Income tax expenseRMB'000 (659,784)(397,227) PDF p. 82
Profit for the yearRMB'000 1,443,2771,613,080 PDF p. 82
Other comprehensive income - not reclassified
Fair value gain (loss) on investments in equity instruments at fair value through other comprehensive incomeRMB'000 227,810(34,110) PDF p. 82
Other comprehensive income - may be reclassified
Share of other comprehensive (expense) income of associatesRMB'000 (6,568)6,162 PDF p. 82
Exchange differences arising on translation of foreign operationsRMB'000 (8,284)3,038 PDF p. 82
Exchange differences arising on translation of interests in associatesRMB'000 15,664(9,061) PDF p. 82
Other comprehensive income
Other comprehensive income (expense) for the year, net of income taxRMB'000 228,622(33,971) PDF p. 82
Total comprehensive income
Total comprehensive income for the yearRMB'000 1,671,8991,579,109 PDF p. 82
Profit (loss) for the year attributable to
Owners of the CompanyRMB'000 1,488,8921,619,788 PDF p. 82
Non-controlling interestsRMB'000 (45,615)(6,708) PDF p. 82
Total comprehensive income (expense) attributable to
Owners of the CompanyRMB'000 1,717,5141,585,817 PDF p. 82
Non-controlling interestsRMB'000 (45,615)(6,708) PDF p. 82
Earnings per share
BasicRMB 0.61540.6673 PDF p. 82
Definitions & sources

Earnings per share in RMB. Statement is for the Group only; no separate company-level statement printed on this page.

Consolidated Statement of Cash Flows (Group) - operating and investing

59 metrics

Units appear below each metric. Scroll to compare years

Consolidated Statement of Cash Flows (Group) - operating and investing from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, year ended 31 Dec 2025, RMB'0002024Group, year ended 31 Dec 2024, RMB'000 Source
Operating activities
Profit before taxRMB'000 2,103,0612,010,307 PDF p. 86
Operating activities - adjustments
Amortisation of intangible assetsRMB'000 199,101184,983 PDF p. 86
Impairment loss on interest in an associateRMB'000 20,000100,000 PDF p. 86
Write-down of inventoriesRMB'000 20,000- PDF p. 86
Impairment loss recognised (reversed) on financial assets under expected credit loss model, net of reversalRMB'000 1,723(499) PDF p. 86
Impairment loss on deposit paid for acquisition of intangible assetsRMB'000 31,7401,152 PDF p. 86
Interest expensesRMB'000 20,29738,610 PDF p. 86
Share-based payment expenseRMB'000 27,310- PDF p. 86
Depreciation of property, plant and equipmentRMB'000 47,23650,755 PDF p. 86
Depreciation of right-of-use assetsRMB'000 20,59123,500 PDF p. 86
Loss (gain) on disposal of property, plant and equipmentRMB'000 867(500) PDF p. 86
Share of results of associatesRMB'000 (238,790)(338,548) PDF p. 86
Share of result of a joint ventureRMB'000 (3,505)(2,755) PDF p. 86
Interest incomeRMB'000 (82,348)(126,344) PDF p. 86
Dividends from financial assets at fair value through profit or lossRMB'000 (32,068)(1,716) PDF p. 86
Net foreign exchange lossRMB'000 5,1104,500 PDF p. 86
Change in fair value of derivative financial instrumentsRMB'000 -(17,227) PDF p. 86
Change in fair value of financial assets at fair value through profit or lossRMB'000 (230,987)9,025 PDF p. 86
Gain on disposal of a subsidiaryRMB'000 (19,594)- PDF p. 86
Operating activities
Operating cash flows before movements in working capitalRMB'000 1,889,7441,935,243 PDF p. 86
Operating activities - working capital
Increase in inventoriesRMB'000 (55,905)(130,503) PDF p. 86
Increase in trade and other receivables and prepaymentsRMB'000 (446,763)(173,422) PDF p. 86
(Increase) decrease in amounts due from associatesRMB'000 (164,405)124,079 PDF p. 86
Increase in trade and other payablesRMB'000 22,76847,821 PDF p. 86
(Decrease) increase in contract liabilitiesRMB'000 (4,477)3,877 PDF p. 86
Operating activities
Cash generated from operationsRMB'000 1,240,9621,807,095 PDF p. 87
People’s Republic of China (the “PRC”) Enterprise Income Tax paidRMB'000 (427,426)(386,506) PDF p. 87
Hong Kong Profits Tax paidRMB'000 (1,301)(79,100) PDF p. 87
Macau Complementary Income Tax paidRMB'000 (40,356)(72,942) PDF p. 87
Income tax payments in other countriesRMB'000 (13,458)- PDF p. 87
Net cash from operating activitiesRMB'000 758,4211,268,547 PDF p. 87
Investing activities
Interest receivedRMB'000 82,348126,344 PDF p. 87
Dividend received from an associateRMB'000 225,276184,691 PDF p. 87
Dividend received from a joint ventureRMB'000 13,001- PDF p. 87
Dividends received from financial assets at fair value through profit or lossRMB'000 32,0681,716 PDF p. 87
Purchase of property, plant and equipmentRMB'000 (41,037)(32,619) PDF p. 87
Proceeds from disposal of property, plant and equipmentRMB'000 1,3694,087 PDF p. 87
Disposal of financial assets at fair value through profit or lossRMB'000 14,4786,007 PDF p. 87
Purchase of financial assets at fair value through profit or lossRMB'000 (708,296)(342,871) PDF p. 87
Purchase of intangible assetsRMB'000 -(114,674) PDF p. 87
Proceeds on disposal of an interest in an associateRMB'000 8,008- PDF p. 87
Deposits paid for acquisition of intangible assetsRMB'000 (473,374)(308,615) PDF p. 87
Capital injection to associatesRMB'000 (125,165)(66,935) PDF p. 87
Net cash inflow on disposal of a subsidiaryRMB'000 34,991- PDF p. 87
Loan to third partiesRMB'000 (47,989)(72,227) PDF p. 87
NET CASH USED IN INVESTING ACTIVITIESRMB'000 (984,322)(615,096) PDF p. 87
Financing activities
New bank borrowings raisedRMB'000 682,515831,300 PDF p. 88
Repayment for deferred consideration payableRMB'000 -(1,000) PDF p. 88
Interest paidRMB'000 (20,297)(38,610) PDF p. 88
Dividends paidRMB'000 (660,555)(556,162) PDF p. 88
Repayment of bank borrowingsRMB'000 (862,000)(1,274,150) PDF p. 88
Repayments of lease liabilitiesRMB'000 (18,961)(22,217) PDF p. 88
Payment on repurchase of sharesRMB'000 -(238,394) PDF p. 88
Capital contribution from non-controlling interestsRMB'000 108,36238,187 PDF p. 88
NET CASH USED IN FINANCING ACTIVITIESRMB'000 (770,936)(1,261,046) PDF p. 88
Net change in cash
NET DECREASE IN CASH AND CASH EQUIVALENTSRMB'000 (996,837)(607,595) PDF p. 88
CASH AND CASH EQUIVALENT AT THE BEGINNING OF YEARRMB'000 3,706,5014,311,058 PDF p. 88
Effects of exchange rate changes on the balance of cash held in foreign currenciesRMB'000 (8,284)3,038 PDF p. 88
Closing cash
CASH AND CASH EQUIVALENT AT THE END OF YEAR REPRESENTED BY BANK BALANCES AND CASHRMB'000 2,701,3803,706,501 PDF p. 88
Definitions & sources

Spans physical pages 86-88; page 88 is headed 'Consolidated statement of financial position (continued)' but contains the financing section.

Consolidated Statement of Changes in Equity (Group) - 2024 and 2025 movements

26 metrics

Units appear below each metric. Scroll to compare years

Consolidated Statement of Changes in Equity (Group) - 2024 and 2025 movements from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Share capital, RMB'0002025Share premium, RMB'0002025Capital reserve (Note 32), RMB'0002025Surplus reserve fund (Note 32), RMB'0002025Translation reserve, RMB'0002025Investments revaluation reserve, RMB'0002025Accumulated profits, RMB'0002025Dividend reserve, RMB'0002025Treasury Stock, RMB'0002025Sub-total attributable to owners of the Company, RMB'0002025Attributable to non-controlling interests, RMB'0002025Total, RMB'000 Source
Opening 2024
Balance at 1 January 2024RMB'000 83,9912,105,62119,545425,63565,052(371,956)13,000,329191,991-15,520,20836,19915,556,407 PDF p. 85
Year 2024
Profit (loss) for the yearRMB'000 ------1,619,788--1,619,788(6,708)1,613,080 PDF p. 85
Share of other comprehensive income of associatesRMB'000 ----6,162----6,162-6,162 PDF p. 85
Exchange differences arising on translation of foreign operationsRMB'000 ----3,038----3,038-3,038 PDF p. 85
Exchange differences arising on translation of interests in associatesRMB'000 ----(9,061)----(9,061)-(9,061) PDF p. 85
Fair value loss on investments in equity instruments at fair value through other comprehensive incomeRMB'000 -----(34,110)---(34,110)-(34,110) PDF p. 85
Total comprehensive income (expense) for the yearRMB'000 ----139(34,110)1,619,788--1,585,817(6,708)1,579,109 PDF p. 85
Repurchase of ordinary shares in treasury stock (Note 31)RMB'000 --------(238,394)(238,394)-(238,394) PDF p. 85
Cancellation of ordinary shares (Note 31)RMB'000 (427)(80,020)------80,447--- PDF p. 85
Capital contribution from non-controlling interestsRMB'000 ----------62,14862,148 PDF p. 85
Dividends paid (Note 13)RMB'000 ------(364,171)(191,991)-(556,162)-(556,162) PDF p. 85
Dividends proposed (Note 13)RMB'000 ------(283,700)283,700---- PDF p. 85
Transfer of reservesRMB'000 ---13,237--(13,237)----- PDF p. 85
Closing 2024 / opening 2025
Balance at 31 December 2024RMB'000 83,5642,025,60119,545438,87265,191(406,066)13,959,009283,700(157,947)16,311,46991,63916,403,108 PDF p. 85
Year 2025
Profit (loss) for the yearRMB'000 ------1,488,892--1,488,892(45,615)1,443,277 PDF p. 85
Exchange differences arising on translation of foreign operationsRMB'000 ----(8,284)----(8,284)-(8,284) PDF p. 85
Exchange differences arising on translation of interests in associatesRMB'000 ----15,664----15,664-15,664 PDF p. 85
Fair value gain on investments in equity instruments at fair value through other comprehensive incomeRMB'000 -----227,810---227,810-227,810 PDF p. 85
Total comprehensive income (expense) for the yearRMB'000 ----812227,8101,488,892--1,717,514(45,615)1,671,899 PDF p. 85
Distribution of treasury stock to employees (Note 31)RMB'000 -24------27,28627,310-27,310 PDF p. 85
Capital contribution from non-controlling interestsRMB'000 ----------108,362108,362 PDF p. 85
Dividends paid (Note 13)RMB'000 ------(376,855)(283,700)-(660,555)-(660,555) PDF p. 85
Dividends proposed (Note 13)RMB'000 ------(330,641)330,641---- PDF p. 85
Disposal of a subsidiary( Note 40)RMB'000 ----------(7,361)(7,361) PDF p. 85
Transfer of reservesRMB'000 ---1,684--(1,684)----- PDF p. 85
Closing 2025
Balance at 31 December 2025RMB'000 83,5642,025,62519,545440,55666,003(178,256)14,738,721330,641(130,661)17,395,738147,02517,542,763 PDF p. 85
Definitions & sources

Rows cover movements from 1 January 2024 to 31 December 2025 as printed; each row's date/period is in its label. No separate Company-level statement of changes in equity was on the page read.

Summary of Consolidated Statement of Financial Position (five-year)

3 metrics

Units appear below each metric. Scroll to compare years

Summary of Consolidated Statement of Financial Position (five-year) from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2021Group, as at 31 December, RMB'0002022Group, as at 31 December, RMB'0002023Group, as at 31 December, RMB'0002024Group, as at 31 December, RMB'0002025Group, as at 31 December, RMB'000 Source
Summary of Consolidated Statement of Financial Position
Total assetsRMB'000 15,807,87917,753,53917,730,83718,047,79019,198,855 PDF p. 4
Total liabilitiesRMB'000 2,960,8923,016,4622,174,4301,644,6821,656,092 PDF p. 4
Net assetsRMB'000 12,846,98714,737,07715,556,40716,403,10817,542,763 PDF p. 4
Definitions & sources

Only the balance sheet summary spans five years; no five-year income or cash flow summary is printed.

Financial Highlights (bullet points, 2025 vs 2024)

8 metrics

Units appear below each metric. Scroll to compare years

Financial Highlights (bullet points, 2025 vs 2024) from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, year ended 31 December 2025, RMB (million unless stated)2024Group, year ended 31 December 2024, comparative, RMB (million unless stated) Source
Financial Highlights
TurnoverRMB million 8,212.17,469.0 PDF p. 4
Turnover (in the case that all medicines were directly sold by the Group)RMB million 9,385.68,621.6 PDF p. 4
Gross profitRMB million 5,871.55,422.2 PDF p. 4
Gross profit (in the case that all medicines were directly sold by the Group)RMB million 5,852.05,405.4 PDF p. 4
Profit for the yearRMB million 1,443.31,613.1 PDF p. 4
Normalized profit for the year*RMB million 1,775.51,713.7 PDF p. 4
Basic earnings per shareRMB per share 0.61540.6673 PDF p. 4
Total dividend for the yearRMB per share 0.29210.2681 PDF p. 4
Definitions & sources

* Normalized profit for the year of 2025 mainly refers to excluding a one-off payment of RMB278.8 million, consisting of the repayment of the local income tax concession enjoyed for the years from 2022 to 2024 and the related late payment surcharge.

Bank balances and cash printed only for 31 December 2025 in this bullet; 2024 value (RMB3,706.5 million) appears in MD&A. 2024 total dividend 0.2681 and final 0.1174 are from the same bullet.

Summary of consolidated statements of cash flows (MD&A)

7 metrics

Units appear below each metric. Scroll to compare years

Summary of consolidated statements of cash flows (MD&A) from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, year ended 31 December 2025, RMB'0002024Group, year ended 31 December 2024, RMB'000 Source
Management Discussion and Analysis - cash flow summary
Net cash from operating activitiesRMB'000 758,4211,268,547 PDF p. 42
Net cash used in investing activitiesRMB'000 (984,322)(615,096) PDF p. 42
Net cash used in financing activitiesRMB'000 (770,936)(1,261,046) PDF p. 42
Net decrease in cash and cash equivalentRMB'000 (996,837)(607,595) PDF p. 42
Cash and cash equivalent at beginning of the yearRMB'000 3,706,5014,311,058 PDF p. 42
Effect of foreign exchange rate changesRMB'000 (8,284)3,038 PDF p. 42
Cash and cash equivalent at end of the yearRMB'000 2,701,3803,706,501 PDF p. 42
Definitions & sources

Net Current Assets (MD&A)

14 metrics

Units appear below each metric. Scroll to compare years

Net Current Assets (MD&A) from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, as at 31 December 2025, RMB'0002024Group, as at 31 December 2024, RMB'000 Source
Current Assets
InventoriesRMB'000 803,958768,139 PDF p. 43
Financial assets at fair value through profit or lossRMB'000 3,084,9022,160,097 PDF p. 43
Trade receivablesRMB'000 1,587,8741,222,479 PDF p. 43
Other receivables and prepaymentsRMB'000 670,692558,004 PDF p. 43
Tax recoverableRMB'000 1,2705,553 PDF p. 43
Amount due from associatesRMB'000 448,493284,088 PDF p. 43
Bank balances and cashRMB'000 2,701,3803,706,501 PDF p. 43
Current Liabilities
Trade payablesRMB'000 106,575142,432 PDF p. 43
Other payablesRMB'000 389,141342,365 PDF p. 43
Lease liabilitiesRMB'000 16,59716,933 PDF p. 43
Contract liabilitiesRMB'000 12,13316,610 PDF p. 43
Bank borrowingsRMB'000 651,815831,300 PDF p. 43
Tax liabilitiesRMB'000 292,962166,423 PDF p. 43
Net Current Assets
Net current assetsRMB'000 7,829,3467,188,798 PDF p. 43
Definitions & sources

Subtotals for current assets (9,298,569 / 8,704,861) and current liabilities (1,469,223 / 1,516,063) are printed unlabelled and not extracted as rows.

Capital expenditure and debt/gearing (MD&A)

3 metrics

Units appear below each metric. Scroll to compare years

Capital expenditure and debt/gearing (MD&A) from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, year ended / as at 31 December 2025, RMB'0002024Group, year ended / as at 31 December 2024, RMB'000 Source
Capital Expenditures
Deposits for acquisition of intangible assetsRMB'000 473,374423,289 PDF p. 43
Purchase of property, plant and equipmentRMB'000 41,03732,619 PDF p. 43
Capital Structure and Gearing Ratio
Interest bearing bank borrowingsRMB'000 651,815831,300 PDF p. 43
Definitions & sources

Total capital expenditure 514,411 / 455,908 printed unlabelled.

Gearing ratio and other ratios stated in MD&A text

6 metrics

Units appear below each metric. Scroll to compare years

Gearing ratio and other ratios stated in MD&A text from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, 2025 (or as at 31 December 2025)2024Group, 2024 (or as at 31 December 2024) Source
Capital Structure and Gearing Ratio
Gearing ratio, calculated as bank borrowings divided by total assets% 3.44.6 PDF p. 44
Gross Profit and Gross Profit Margin
Gross profit margin% 71.572.6 PDF p. 39
Gross profit margin (in the case that all medicines were directly sold by the Group)% 62.462.7 PDF p. 39
Inventories
Average inventory turnover daysdays 123125 PDF p. 41
Trade Receivables
Average trade receivables turnover daysdays 7975 PDF p. 41
Trade Payables
Average trade payables turnover daysdays 1925 PDF p. 41
Definitions & sources

Gearing ratio defined as bank borrowings divided by total assets.

Note 14 Earnings per share

1 metrics

Units appear below each metric. Scroll to compare years

Note 14 Earnings per share from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025
Metric / unit 2025Group, year ended 31 December 20252024Group, year ended 31 December 2024 Source
Number of shares
Weighted average number of ordinary shares for the purpose of basic earnings per sharenumber of shares 2,419,522,1702,427,382,419 PDF p. 125
Definitions & sources

No diluted earnings per share for both 2025 and 2024 were presented as there were no potential ordinary shares in issue for both 2025 and 2024.

Basic EPS RMB0.6154 (2025) and RMB0.6673 (2024) per page 4 highlights.

Where the money comes from

Segment information

By business

Segment revenue and results, year ended 31 December 2025 5 lines
Segment revenue and results, year ended 31 December 2025
Item / unit 2025Integrated Business, RMB'0002025Skin Health Business, RMB'0002025Elimination, RMB'0002025Total, RMB'000 Source
Segment information
External revenueRMB'000 7,146,8281,065,230-8,212,058 PDF p. 115
Inter-segment revenueRMB'000 27,9804,619(32,599)- PDF p. 115
TurnoverRMB'000 7,174,8081,069,849(32,599)8,212,058 PDF p. 115
Gross profitRMB'000 5,223,110674,415(25,989)5,871,536 PDF p. 115
Segment profit (loss) for the yearRMB'000 1,546,972(103,695)-1,443,277 PDF p. 115
Notes

Group reorganised reporting into two segments (Integrated Business and Skin Health Business); prior year segment disclosures represented.

Segment revenue and results, year ended 31 December 2024 (represented) 5 lines
Segment revenue and results, year ended 31 December 2024 (represented)
Item / unit 2024Integrated Business, RMB'0002024Skin Health Business, RMB'0002024Elimination, RMB'0002024Total, RMB'000 Source
Segment information
External revenueRMB'000 6,899,028569,962-7,468,990 PDF p. 116
Inter-segment revenueRMB'000 62,54447,568(110,112)- PDF p. 116
TurnoverRMB'000 6,961,572617,530(110,112)7,468,990 PDF p. 116
Gross profitRMB'000 5,080,862391,860(50,528)5,422,194 PDF p. 116
Segment profit (loss) for the yearRMB'000 1,747,140(105,630)(28,430)1,613,080 PDF p. 116
Notes

Prior year segment disclosures have been represented to conform with current presentation.

Segment assets and liabilities, as at 31 December 2 lines
Segment assets and liabilities, as at 31 December
Item / unit 2025Integrated Business, RMB'0002025Skin Health Business, RMB'0002025Elimination, RMB'0002025Total, RMB'0002024Integrated Business, RMB'0002024Skin Health Business, RMB'0002024Elimination, RMB'0002024Total, RMB'000 Source
Segment assets and liabilities
Segment assetsRMB'000 19,468,4222,635,017(2,904,584)19,198,85518,521,2572,175,853(2,649,320)18,047,790 PDF p. 116
Segment liabilitiesRMB'000 1,554,224110,151(8,283)1,656,0921,653,722224,825(233,865)1,644,682 PDF p. 116
Disaggregation of revenue by product/service (point in time) 3 lines
Disaggregation of revenue by product/service (point in time) — Group
Item / unit 2025RMB'0002024RMB'000 Source
Disaggregation of revenue from contracts with customers
Sales of pharmaceutical productsRMB'000 6,605,2385,887,214 PDF p. 115
Promotion incomeRMB'000 1,606,8201,581,776 PDF p. 115
Total revenueRMB'000 8,212,0587,468,990 PDF p. 115

Debt

Borrowings

Bank borrowings – secured/unsecured and repayment

Bank borrowings – secured/unsecured and repayment — Group
Item / unit 2025RMB'0002024RMB'000 Source
Bank borrowings
Bank loansRMB'000 651,815831,300 PDF p. 153
Analysed as
UnsecuredRMB'000 650,033831,300 PDF p. 153
SecuredRMB'000 1,782- PDF p. 153
Carrying amounts repayable
Within one yearRMB'000 651,815831,300 PDF p. 153
Less: Amounts due within one year shown under current liabilitiesRMB'000 (651,815)(831,300) PDF p. 153
Amounts shown under non-current liabilitiesRMB'000 -- PDF p. 153
Notes

* The amounts due are based on scheduled repayment dates set out in the loan agreements.

As at 31 December 2025, the Group had unutilised banking facilities of approximately RMB 3,895,427,000 (2024: RMB1,880,341,000). And approximately RMB 1,782,000 (2024: Nil) borrowings secured by land, property, plant and equipment.

Liquidity risk maturity – 31 December 2025 (undiscounted)

Liquidity risk maturity – 31 December 2025 (undiscounted) — Group
Item / unit 2025as at 31 December 2025: weighted average interest rate %2025repayable on demand or less than 1 year, RMB'00020251 to 5 years, RMB'0002025total undiscounted cash flows, RMB'0002025carrying amount at 31 December 2025, RMB'000 Source
Non-derivative financial liabilities
Fixed-rate bank borrowings% / RMB'000 2.12665,611-665,611651,815 PDF p. 166
Lease liabilities% / RMB'000 4.7517,38524,50541,89038,264 PDF p. 166
Notes

Table includes both interest and principal cash flows; based on undiscounted cash flows on the earliest date the Group can be required to pay.

Liquidity risk maturity – 31 December 2024 (undiscounted)

Liquidity risk maturity – 31 December 2024 (undiscounted) — Group
Item / unit 2024weighted average interest rate %2024repayable on demand or less than 1 year, RMB'00020241 to 5 years, RMB'0002024total undiscounted cash flows, RMB'0002024carrying amount at 31 December 2024, RMB'000 Source
Non-derivative financial liabilities
Fixed-rate bank borrowings% / RMB'000 2.39851,202-851,202831,300 PDF p. 167
Lease liabilities% / RMB'000 4.7517,73713,72731,46429,443 PDF p. 167
Notes

Table includes both interest and principal cash flows.

Borrowing notes 2 tables

Bank borrowings – interest rates and currency

Bank borrowings – interest rates and currency — Group
Item / unit 2025RMB'0002024RMB'000 Source
Fixed-rate borrowing
Denominated in RMB at fixed rate of 1.00% per annum as at 31 December 2025RMB'000 8,000- PDF p. 153
Denominated in RMB at fixed rate of 1.10% per annum as at 31 December 2024RMB'000 -40,300 PDF p. 153
Denominated in RMB at fixed rate of 1.35% per annum as at 31 December 2024RMB'000 -19,000 PDF p. 153
Denominated in RMB at fixed rate of 1.90% per annum as at 31 December 2025RMB'000 360,000- PDF p. 153
Denominated in RMB at fixed rate of 2.40% per annum as at 31 December 2025 and 2024RMB'000 270,000185,000 PDF p. 153
Denominated in RMB at fixed rate of 2.50% per annum as at 31 December 2025 and 2024RMB'000 5,000500,000 PDF p. 153
Denominated in RMB at fixed rate of 2.51% per annum as at 31 December 2025RMB'000 1,782- PDF p. 153
Denominated in RMB at fixed rate of 2.60% per annum as at 31 December 2024RMB'000 -87,000 PDF p. 153
Denominated in RMB at fixed rate of 3.00% per annum as at 31 December 2025RMB'000 7,033- PDF p. 153
TotalRMB'000 651,815831,300 PDF p. 153
Notes

The ranges of effective interest rates (which are also equal to contractual interest rate) on the Group’s borrowings and their carrying values are as follows. Quotes for rows with wrapped labels use the continuation line containing the values.

Lease liabilities payable

Lease liabilities payable — Group
Item / unit 2025RMB'0002024RMB'000 Source
Lease liabilities payable
Within one yearRMB'000 16,59716,933 PDF p. 152
Within a period of more than one year but not more than two yearsRMB'000 10,7437,192 PDF p. 152
Within a period of more than two years but not more than five yearsRMB'000 10,9245,318 PDF p. 152
Less: Amount due for settlement with 12 months shown under current liabilitiesRMB'000 (16,597)(16,933) PDF p. 152
Amount due for settlement after 12 months shown under non-current liabilitiesRMB'000 21,66712,510 PDF p. 152
Notes

The weighted average incremental borrowing rate applied to lease liabilities is 4.75% for both years.

Total lease liabilities payable of 38,264 (2025) and 29,443 (2024) are printed as an unlabelled subtotal line.

Payout

Dividends & distributions

Dividend policy

ItemValuePeriod / scopeSource
Dividend Policy The Board has adopted a dividend policy (the “Dividend Policy”). Under the Dividend Policy, the Company does not have any pre-determined dividend payout ratio. Although the Company intends to declare and pay dividends in the future, the declaration, payment and amount of any dividends are subject to the Board’s discretion having regard to the following factors: (a) the Group’s actual and expected financial performance; (b) the Group’s expected working capital requirements and future development plans; (c) the Group’s liquidity position; (d) the economic outlook; (e) contractual restrictions or obligations; (f) shareholders’ interests; and (g) any other factors the Board may consider relevant. Company PDF p. 50

Dividends declared and proposed

ItemValuePeriod / scopeSource
2025 Interim - RMB0.1555 (2024: 2024 Interim dividend RMB0.1555 2025 interim dividend per share, paid during 2025 PDF p. 125
RMB0.1507) per share RMB0.1507 2024 interim dividend per share (comparative) PDF p. 125
2025 final - RMB 0.1366 (2024: 2024 final RMB 0.1366 2025 proposed final dividend per share PDF p. 125
2024 Final - RMB0.1174 (2024: 2023 final dividend RMB0.1174 2024 final dividend per share (comparative), paid during 2025 PDF p. 125
Final Dividend RMB0.1366 (equivalent to HKD0.155 and SGD0.025) per ordinary Share 2025 final dividend PDF p. 49

Payout

ItemValuePeriod / scopeSource
total dividend for the year ended 31 December 2025 RMB0.2921 per share Total dividend for 2025 (interim + proposed final); 2024 total RMB0.2681 per share, increase of 9.0% PDF p. 4
total dividend of RMB0.2681 per share RMB0.2681 per share Total dividend for 2024 (comparative) PDF p. 4

Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.

Auditor’s report

Audit & risk signals

Audit opinion

ItemValuePeriod / scopeSource
Deloitte Touche Tohmatsu Deloitte Touche Tohmatsu Group consolidated financial statements, year ended 31 December 2025 PDF p. 81
Engagement partner Sy, Sunnie (practising certificate number: P06034) Group consolidated financial statements, year ended 31 December 2025 PDF p. 81
Opinion In our opinion, the consolidated financial statements give a true and fair view Group consolidated financial statements, year ended 31 December 2025 PDF p. 77

Extracted from CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025 and checked against the cited pages; see the original report for full context.

How to read these figures

Group and parent company or bank figures are labelled separately. Parentheses indicate negative amounts; a dash and NA retain the report’s notation.

Comparative figures follow CHINA MEDICAL SYSTEM HOLDINGS LIMITED ANNUAL REPORT 2025, including retrospective adjustments. Adjusted and reported earnings may have different definitions; refer to each statement’s notes.

These tables show the available extracted figures. The original annual report contains the full statements, notes and definitions.